Janssen Biotech and Astellas Pharma have entered into a license agreement for the worldwide development and commercialization (except in Japan) of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor currently in Phase II development as a treatment for moderate-to-severe rheumatoid arthritis (RA) and plaque psoriasis.   Janssen, a J&J subsidiary, gains exclusive worldwide rights to ASP015K for immune-mediated inflammatory diseases. Astellas will receive an undisclosed upfront paymen...